ERBB2 and colorectal carcinoma: Trastuzumab deruxtecan has demonstrated promising activity in HER2‐expressing CRC, while the combination of pertuzumab and trastuzumab has shown efficacy in HER2‐amplified, heavily pretreated, relapsed CRC patients, as reported in two separate phase II clinical trials [91, 92].